Andere talen Xeris Biopharma Holdings, Inc.

Aandelen

XERS

US98422E1038

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,85 ^USD	+5,71%		+8,82%	-21,28%

28/03	XERIS BIOPHARMA HOLDINGS, INC. : Oppenheimer verhoogt advies van Neutraal naar Kopen	ZM
06/03	Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024	02/05
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03/04
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference	02/04
Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index	18/03
Xeris Biopharma: Q4 Earnings Snapshot	06/03
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q4 Revenue $44.4M, vs. Street Est of $43.6M	06/03
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events	06/03
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital	06/03
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024	06/03
Xeris Refinances its $150 Million Senior Secured Term Loan Facility with Hayfin Capital	06/03
North American Morning Briefing : Stock Futures -2-	06/03
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024	28/02
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference	05/02
Xeris Biopharma Holdings Seeks Acquisitions	11/01
US Equity Markets Close Higher Wednesday as Investors Await Inflation Data	10/01
Sector Update: Health Care Stocks Gain Late Afternoon	10/01
Xeris Biopharma Shares Rise on Licensing Agreement With Amgen	10/01
Xeris Biopharma Shares Climb 12% on Amgen License Agreement	10/01
Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment	10/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Xeris Biopharma Holdings, Inc.

Aandelen

XERS

US98422E1038

Andere talen

Filters